Effects of 5-HT(1A) receptor antagonists on fluoxetine-induced changes in extracellular serotonin concentrations in rat frontal cortex

European Journal of Pharmacology

Volumn 345, Issue 1, 1998, Pages 41-46

  Dawson, L A ^a   Nguyen, H Q ^a  

^a PFIZER INC   (United States)

Author keywords

5 HT (5 hydroxytryptamine, serotonin); 5 HT(1A) receptor agonist; Fluoxetine, 5 HT(1A) receptor antagonist; Microdialysis, 5 HT(1A) receptor

Indexed keywords

BUSPIRONE; FLUOXETINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N TERT BUTYL 3 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL] 2 PHENYLPROPIONAMIDE; PINDOLOL; SEROTONIN; SEROTONIN 1A ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; CYCLOHEXANE DERIVATIVE; PIPERAZINE DERIVATIVE; PYRIDINE DERIVATIVE; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; WAY 101363;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; FRONTAL CORTEX; MALE; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT; SEROTONIN BRAIN LEVEL; SEROTONINERGIC SYSTEM; SUBCUTANEOUS DRUG ADMINISTRATION; ANIMAL; EXTRACELLULAR SPACE; METABOLISM; PREFRONTAL CORTEX; SPRAGUE DAWLEY RAT;

ANIMALS; BUSPIRONE; CYCLOHEXANES; EXTRACELLULAR SPACE; FLUOXETINE; MALE; MICRODIALYSIS; PIPERAZINES; PREFRONTAL CORTEX; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS;

EID: 0032510218     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)01580-X     Document Type: Article

References (37)

1. Adell A., Artigas F. Differential effects of clomipramine given locally or systemically on extracellular 5-hydroxytryptamine in the raphe nuclei and frontal cortex. Naunyn Schmiedebergs Arch. Pharmacol. 343:1991;237-244.
2. Artigas F., Perez V., Alvarez E. Pindolol induces a rapid improvement of patients with depression treated with serotonin reuptake inhibitors. Arch. Gen. Psychiatry. 51:1994;248-251.
3. Assie M.B., Koek W. Effects of 5-HT1A receptor antagonists on hippocampal 5-hydroxytryptamine levels: (S)-WAY100135, but not WAY100635, has partial agonist properties. Eur. J. Pharmacol. 304:1996;15-21.
4. Berman R.M., Darnell A.M., Miller H.L., Anand A., Charney D.S. Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: A double-blind, placebo-controlled trial. Am. J. Psychiatry. 154:1997;37-43.
5. Blier P., Bergeron R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J. Clin. Psychopharmacol. 15:1995;217-222.
6. Blier P., De Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol. Sci. 15:1994;220-226.
7. Blier P., De Montigny C., Chaput Y. Modifications of the serotonin system by antidepressant treatments: Implications for the therapeutic response in major depression. J. Clin. Psychopharmacol. 7:1987;24-35.
8. Briley M., Moret C. Neurobiological mechanisms involved in antidepressant therapies. Clin. Neuropharmacol. 16:1993;387-400.
9. Dawson L.A., Routledge C. Differential effects of potassium channel blockers on extracellular levels of serotonin and dopamine in the striatum of conscious rats. Br. J. Pharmacol. 116:1996;3260-3264.
10. Delgado J.M.R., Charney D.S., Price L.H., Aghajanian G.K., Landis H., Heninger G.R. Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch. Gen. Psychiatry. 47:1990;411-418.
11. 1A receptors. Neurochem. Res. 21:1996;557-562.
12. Escandon N.A., Zimmermann D.C., McCall R.B. Characterisation of the serotonin 1A receptor antagonist activity of WAY100135 and spiperone. J. Pharmacol. Exp. Ther. 268:1994;441-445.
13. 1A receptor antagonist, Br. J. Pharmacol. 112 (Suppl.), 91.
14. 1A receptor antagonist, WAY100635. Eur. J. Pharmacol. 281:1995;81.
15. 1A autoreceptors in the mechanism of action of serotonergic antidepressant drugs: Recent findings from in vivo microdialysis studies. Fundam. Clin. Pharmacol. 10:1996;16-27.
16. 1A receptor antagonist and an SSRI in vivo: Effects on 5-HT cell firing and extracellular 5-HT. Br. J. Pharmacol. 115:1995;1064-1070.
17. Gobert A., Rivet J.-M., Cistarelli L., Millan M.J. Buspirone enhances duloxetine- and fluoxetine-induced increases in dialysate levels of dopamine and noradrenaline, but not serotonin, in the frontal cortex of freely moving rats. J. Neurochem. 68:1997;1326-1329.
18. 1A autoreceptor blockade potentiates the ability of the 5-HT reuptake inhibitor citalopram to increase nerve terminal output of 5-HT in vivo: A microdialysis study. J. Neurochem. 60:1993;776-779.
19. Hjorth S. (-) Pindolol, but not buspirone, potentiates the citalopram-induced rise in extracellular 5-hydroxytryptamine. Eur. J. Pharmacol. 303:1996;183-186.
20. Hjorth S., Carlsson A. Buspirone: Effects on central monoaminergic transmission-possible relevance to animal experimental and clinical findings. Eur. J. Pharmacol. 83:1982;299-303.
21. 1A autoreceptors and the mode of action of selective serotonin reuptake inhibitors (SSRI). Behav. Brain Res. 73:1996;281-283.
22. Hjorth S., Westlin D., Bengtsson H.J. Relative importance of 5-HT reuptake inhibition and 5-HT1A autoreceptor blockade in the citalopram plus WAY100635-induced elevation of extracellular 5-HT in the rat brain in vivo. Soc. Neurosci. Abstr. 22:1996;527.5.
23. Hyttel J. Pharmacological characterization of the selective serotonin reuptake inhibitors (SSRI's). Int. Clin. Psychopharmacol. 9:1994;19-26.
24. Invernizzi R., Belli S., Samanin R. Citalopram's ability to increase the extracellular concentrations of serotonin in the dorsal raphe prevents the drugs effects in the frontal cortex. Brain Res. 584:1992;322-325.
25. 1A receptors in the effects of acute and chronic fluoxetine on extracellular serotonin in the frontal cortex. Pharmacol. Biochem. Behav. 54:1996;143-147.
26. Jacobsen F.M. Possible augmentation of antidepressant response by buspirone. J. Clin. Psychiatry. 52:1991;217-220.
27. Joffe R.T., Schuller D.R. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. J. Clin. Psychiatry. 54:1993;269-274.
28. Malagie I., Trillat A.C., Jacquot C., Gardier A.M. Effects of acute fluoxetine on extracellular serotonin levels in the raphe: An in vivo microdialysis study. Eur. J. Pharmacol. 286:1995;213-217.
29. Paxinos, G., Watson, C., 1986. The Rat Brain in Stereotaxic Coordinates. Academic Press, New York.
30. Perez V., Gilaberte I., Faries D., Alvarez E., Artigas F. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet. 349:1997;1594-1597.
31. 1A receptors: In vivo microdialysis and electrophysiological studies in the rat brain. Neuropsychopharmacology. 15:1996;349-360.
32. 1A receptor antagonist WAY100135: An in vivo microdialysis study. Eur. J. Pharmacol. 239:1993;195-202.
33. Rutter J.J., Gundlah C., Auerbach S.B. Increase in extracellular serotonin produced by uptake inhibitors is enhanced after chronic treatment with fluoxetine. Neurosci. Lett. 171:1994;183-186.
34. Sharp T., Bramwell S.R., Grahame-Smith D.G. 5-HT1 agonists reduce 5-hydroxytryptamine release in rat hippocampus in vivo as determined by brain microdialysis. Br. J. Pharmacol. 96:1989;283-290.
35. 1B agonists: A comparative study with dorsal neurones. Neuropharmacology. 27:1987;707-712.
36. 1A receptors and pharmacotherapy. Psychopharmacol. Bull. 30:1994;39-43.
37. 1A compounds varying in intrinsic activity. Soc. Neurosci. Abstr. 23:1997;60.21.